← Leaderboards
Jesse Benjamin Mez
Icahn School Of Medicine At Mount Sinai
$11,121,676
Attributed
$16,227,910
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,227,910 · 8
By mechanism
R01$9,125,102 · 3
P30$5,234,701 · 2
U54$1,229,060 · 2
K23$639,047 · 1
Top collaborators
- Kristen Dams-O'Connor6 shared
- Michael Alosco3 shared
- Lee E Goldstein3 shared
- Jonathan D Cherry1 shared
- Vijaya B. Kolachalama1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Eva Velthorst$1,337,197
- Abraham Reichenberg$11,905,270
- Luz Claudio$12,605,746
- Indu A Ayappa$10,906,648
- Bachir Taouli$9,208,757
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMemoryPathologicBrainS DiseaseFundingConsensusDementiaDiagnosisReportingChronic Traumatic EncephalopathyParticipantNeuropathologyHead ImpactS Disease Related DementiaSamplingRisk FactorsGeneticCohortPathologyCognitionLifeNerve DegenerationBoston
Grant awards (26)
Core B: Clinical Core$910,792
P30 · FY2025 · AG · contact PI
Digital Neurodegenerative Pathology After Repetitive Head Impacts$843,248
R01 · FY2025 · NS · contact PI
Validation of Lens Beta-Amyloid as a Novel Biomarker for Early Detection of Alzheimer's Disease at the Boston University Alzheimer's Disease Research$782,114
R01 · FY2025 · AG
Core B: Clinical Core$910,792
P30 · FY2024 · AG · contact PI
Validation of Lens Beta-Amyloid as a Novel Biomarker for Early Detection of Alzheimer's Disease at the Boston University Alzheimer's Disease Research$811,737
R01 · FY2024 · AG
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$1,045,435
R01 · FY2023 · AG
Core B: Clinical Core$910,792
P30 · FY2023 · AG · contact PI
Validation of Lens Beta-Amyloid as a Novel Biomarker for Early Detection of Alzheimer's Disease at the Boston University Alzheimer's Disease Research$824,998
R01 · FY2023 · AG
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$415,010
R01 · FY2023 · AG
Clinicopathological Correlation in Chronic Traumatic Encephalopathy (CTE) and Chronic Traumatic Brain Injury (cTBI)$244,419
U54 · FY2023 · NS · contact PI
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$1,049,417
R01 · FY2022 · AG
Core B: Clinical Core$911,150
P30 · FY2022 · AG · contact PI
Clinicopathological Correlation in Chronic Traumatic Encephalopathy (CTE) and Chronic Traumatic Brain Injury (cTBI)$251,384
U54 · FY2022 · NS · contact PI
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$1,057,765
R01 · FY2021 · AG
Core B: Clinical Core$892,093
P30 · FY2021 · AG · contact PI
Clinicopathological Correlation in Chronic Traumatic Encephalopathy (CTE) and Chronic Traumatic Brain Injury (cTBI)$244,419
U54 · FY2021 · NS · contact PI
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$1,109,803
R01 · FY2020 · AG
Clinicopathological Correlation in Chronic Traumatic Encephalopathy (CTE) and Chronic Traumatic Brain Injury (cTBI)$244,419
U54 · FY2020 · NS · contact PI
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)$1,185,575
R01 · FY2019 · AG
Core B: Clinical Core$699,082
P30 · FY2019 · AG · contact PI
Clinicopathological Correlation in Chronic Traumatic Encephalopathy (CTE) and Chronic Traumatic Brain Injury (cTBI)$244,419
U54 · FY2019 · NS · contact PI
Genetic and Neuropsychological Heterogeneity in Alzheimer's Disease$125,187
K23 · FY2018 · AG · contact PI
Genetic and Neuropsychological Heterogeneity in Alzheimer's Disease$125,187
K23 · FY2017 · AG · contact PI
Genetic and Neuropsychological Heterogeneity in Alzheimer's Disease$129,155
K23 · FY2016 · AG · contact PI
Genetic and Neuropsychological Heterogeneity in Alzheimer's Disease$129,155
K23 · FY2015 · AG · contact PI
Genetic and Neuropsychological Heterogeneity in Alzheimer's Disease$130,363
K23 · FY2014 · AG · contact PI